{"id":960895,"date":"2026-05-11T16:09:46","date_gmt":"2026-05-11T20:09:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rgc-shareholder-alert-regencell-bioscience-holdings-limited-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky\/"},"modified":"2026-05-11T16:09:46","modified_gmt":"2026-05-11T20:09:46","slug":"rgc-shareholder-alert-regencell-bioscience-holdings-limited-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rgc-shareholder-alert-regencell-bioscience-holdings-limited-securities-class-action-lawsuit-investors-with-losses-may-contact-levi-korsinsky\/","title":{"rendered":"RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit – Investors With Losses May Contact Levi & Korsinsky"},"content":{"rendered":"

\nKey Dates and Disclosure Events Shareholders Need to Know: How Regencell’s Stock Surged 48,650% on No Fundamental News Before a DOJ Subpoena Wiped Out $3.09 Per Share
\n<\/h2>\n
\n

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP encourages investors who suffered losses in Regencell Bioscience Holdings Limited (NASDAQ: RGC) to contact the firm. Those who purchased RGC securities between October 28, 2024 and October 31, 2025 may be entitled to recover damages.\u00a0Find out if you qualify to recover losses<\/u><\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/u><\/a> or (212) 363-7500.<\/p>\n

Shares fell $3.09, or 18.56%, to close at $13.56 on November 3, 2025, after the Company disclosed a DOJ subpoena and investigation into trading in its ordinary shares. Investors have until June 23, 2026 to seek lead plaintiff status.<\/p>\n

\n October 28, 2024: The Class Period Opens<\/strong>\n <\/p>\n

Regencell filed its 2024 annual report on Form 20-F with the SEC. The filing contained generic risk factor language warning that Regencell’s shares “may be very thinly traded” and that prices “may be highly volatile.” As alleged, these warnings failed to address the Company’s actual vulnerability to market manipulation or the specific risks that manipulation posed. At this time, the Company’s shares traded below 30 cents.<\/p>\n

\n May 1, 2025: The Unexplained Surge Begins<\/strong>\n <\/p>\n

Regencell’s share price suddenly jumped to $2.03 per share, the lawsuit contends, without any corresponding news about the Company’s business fundamentals. By the end of May, shares were trading around $20.00, an approximate 900% increase in a single month. Regencell had twelve employees, no revenue, no approved products, and R&D spending of roughly $1 million annually.<\/p>\n

\n June 2, 2025: The 38-for-1 Stock Split Announcement<\/strong>\n <\/p>\n

The Company announced a forward stock split, stating it was “intended to enhance liquidity” and “make the shares more accessible to investors.” The action claims this announcement further fueled speculative trading disconnected from business reality.<\/p>\n

\n June 17, 2025: The $78.00 Peak<\/strong>\n <\/p>\n

Regencell shares closed at a Class Period high of $78.00, a 48,650% increase from the start of the Class Period. By the following week, shares had collapsed to slightly above $20.00. According to the filing, no Company disclosures explained the surge.<\/p>\n

\n June 30, 2025: Volatility Acknowledgment Without Disclosure<\/strong>\n <\/p>\n

Regencell filed interim financial results acknowledging that its “stock price has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of our company.” The complaint asserts management attributed volatility to short sellers and third-party media rather than disclosing the potential role of market manipulation or the regulatory exposure it created.<\/p>\n

\n October 31, 2025: The DOJ Subpoena Revealed<\/strong>\n <\/p>\n

Regencell disclosed that it “received correspondence and a subpoena from the U.S. Department of Justice,” indicating an investigation into trading in the Company’s shares. The DOJ requested documents on “corporate operational, financial and accounting matters.” The Company warned it “may be required to pay fines, penalties, damages or settlement costs.”<\/p>\n

\n Chronology of Material Events<\/strong>\n <\/p>\n